Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice

Simona Di Giambenedetto, Arturo Ciccullo, Gianmaria Baldin, Alex Dusina, Arianna Emiliozzi, Davide Moschese, Francesca Lombardi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

7 Citazioni (Scopus)

Abstract

Bone toxicity is a well-known side effect of several antiviral agents. In a cohort of virologically suppressed HIV-infected patients, we investigated the effects of a lamivudine/dolutegravir dual therapy on bone mineral density (BMD). We observed a significant improvement in lumbar spine BMD as well as T-score after 12 months of observation with concomitant bisphosphonate therapy independently predicting a greater improvement. These preliminary data show a favorable effect of this 2-drug regimen on bone health.
Lingua originaleEnglish
pagine (da-a)336-340
Numero di pagine5
RivistaLE INFEZIONI IN MEDICINA
Volume26
Stato di pubblicazionePubblicato - 2018

Keywords

  • Anti-HIV Agents
  • Bone Density
  • Drug Combinations
  • Drug Substitution
  • Female
  • HIV Infections
  • HIV Integrase Inhibitors
  • Heterocyclic Compounds, 3-Ring
  • Humans
  • Lamivudine
  • Male
  • Middle Aged
  • Retrospective Studies

Fingerprint Entra nei temi di ricerca di 'Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice'. Insieme formano una fingerprint unica.

Cita questo